Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Background: Empagliflozin slowed the progression of CKD in patients with type 2 diabetes and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical approach, we assessed treatment differences in kidney function by analyzing slopes of eGFR changes. Methods: Participants ( n =7020) were randomized (1:1:1) to empagliflozin 10 mg/d, empagliflozin 25 mg/d, or placebo added to standard of care. We calculated eGFR slopes using random-intercept/random-coefficient models for prespecified study periods: treatment initiation (baseline to week 4), chronic maintenance treatment (week 4 to last value on treatment), and post-treatment (last value on treatment to follow-up). Results: Compared with placebo, empagliflozin was associated with uniform shifts in individual eGFR slopes across all periods. On treatment initiation, adjusted mean slope (eGFR change per week, ml/min per 1.73 m 2 ) decreased with empagliflozin (−0.77; 95% confidence interval, −0.83 to −0.71; placebo: 0.01; 95% confidence interval, −0.08 to 0.10; P <0.001). However, annual mean slope (ml/min per 1.73 m 2 per year) did not decline with empagliflozin during chronic treatment (empagliflozin: 0.23; 95% confidence interval, 0.05 to 0.40; placebo: −1.46; 95% confidence interval, −1.74 to −1.17; P <0.001). After drug cessation, the adjusted mean eGFR slope (ml/min per 1.73 m 2 per week) increased and mean eGFR returned toward baseline level only in the empagliflozin group (0.56; 95% confidence interval, 0.49 to 0.62; placebo −0.02; 95% confidence interval, −0.12 to 0.08; P <0.001). Results were consistent across patient subgroups at higher CKD risk. Conclusions: The hemodynamic effects of empagliflozin, associated with reduction in intraglomerular pressure, may contribute to long-term preservation of kidney function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The cardiovascular and kidney bene fi ts appear independent of glucose-lowering, suggesting other mechanisms for organ protection, such as reduction in intraglomerular pressure and single-nephron hyper fi ltration leading to preservation of kidney function. 105”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This incident or worsening nephropathy outcome was lower in the empagli fl ozin group -12.7% versus 18.8% -with a HR of 0.61 (95% CI: 0.53 -0.70).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2i conferred less annual eGFR decline and a reduction in albuminuria or decreased progression to severely increased albuminuria.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredIn the citing paper
“Clinically this is manifested by an acute drop in the estimated glomerular filtration rate (eGFR) of approximately 4 to 6 mL/min/1.73m 2 in the first weeks after initiation of SGLT2 inhibition.”
From A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors (2021) · cites this paper as Wanner et al., 2018
In the citing paper
“Importantly, this drop in eGFR is associated with a preservation of long-term kidney function during prolonged treatment and is reversible soon after discontinuation of SGLT2 inhibitors (Wanner et al., 2018).”
From A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors (2021) · cites this paper as Wanner et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationDe Rosa, S., Samoni, S., Villa, G., & Ronco, C. (2017) · Blood Purification · doi:10.1159/000452650 · Cited by 5,007
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Self-citationGlomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
Self-citationLevey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Self-citation
Cited by
Items 101–200 of 224
Cardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 14
“GLP1 ‐ RAs have been found to reduce the risk of kidney outcomes 16 and an even more pronounced effect has been reported with SGLT2 ‐ is 31 with clear preservation of kidney function (i.e., the slope of eGFR change over time).”
BackgroundClinical trial designs to assess treatment effects on glomerular filtration rate decline
Heerspink, H. J. L., Little, D. J., Frison, L., Gasparyan, S. B., Wanner, C., Jongs, N., & Postmus, D. (2024) · Kidney International · doi:10.1016/j.kint.2024.06.007 · Cited by 14
Self-citationWen, S., Yuan, Y., Li, Y., Xu, C., Chen, L., Ren, Y., Wang, C., He, Y., Li, X., Gong, M., et al. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01985-2 · Cited by 14
Lameire, N. H. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2010008 · Cited by 14
“Successfully decongested heart failure patients [74–76], treatment with ACEIs or ARBs [77] or with sodium-glucose cotransporter-2 (SGLT2) inhibitors [78], and adequate treatment of hypertension [79] are frequently followed by an acute increase in SCr, but also by lower long-term mortality and/or improvement of the und…”
BackgroundChronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i
Zhu, Y., Lv, C., Yang, H., Lü, Q., Wang, X., Zhang, Y., Guo, M., & Yang, B. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2575921 · Cited by 13
“Prominent studies, including eMPa-reG oUtCoMe [109,110], CreDeNCe [111,112] (Canagliflozin and renal endpoints in Diabetes with established Nephropathy Clinical evaluation), and the DeLiver [113] (Dapagliflozin evaluation to improve the Lives of Patients with Preserved ejection fraction heart…”
Watada, H., Yamauchi, T., Yamamoto, F., Taniguchi, A., Yarush, L., Heilmann, C. J., & Yasui, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1782884 · Cited by 13
Hailat, M. M., Zakaraya, Z. Z., Al-Ani, I. H., Meanazel, O. T. A., Al‐Shdefat, R., Anwer, M. K., Saadh, M. J., & Dayyih, W. A. (2022) · Pharmaceuticals · doi:10.3390/ph15020193 · Cited by 13
“73 m2, treatment with this medication should be stopped [8,9].”
BackgroundAlthobaiti, F. M., Alsanosi, S., Falemban, A. H., Alzahrani, A. R., Fataha, S. A., Salih, S. O., Alrumaih, A. M., Alotaibi, K. N., Althobaiti, H. M., Al-Ghamdi, S. S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164769 · Cited by 13
“In addition, haemodynamic effects of EMPA, associated with a reduction in intraglomerular pressure, may contribute to long-term preservation of kidney function [28].”
BackgroundLi, R., Wang, K., Li, M., Liu, H., You, Y., Liu, D., Guo, X., Chen, J., & Wu, S. (2025) · Environmental Research · doi:10.1016/j.envres.2025.122841 · Cited by 12
van der Hoek, S., Jongs, N., Oshima, M., Neuen, B. L., Stevens, J., Perkovic, V., Levin, A., Mahaffey, K. W., Pollock, C. A., Greene, T., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000161 · Cited by 12
Self-citationShah, M., Stolbov, L. A., Yakovleva, T. A., Tang, W., Sokolov, V., Penland, R. C., Boulton, D. W., & PARKINSON, J. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14305 · Cited by 13
IDRIS, I. R., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14799 · Cited by 12
“In combination, HF and CKD further increased the risk of cardiovascular (HR 3.91; 95% CI 3.02-5.07) and all-cause mortality (HR 3.14, 95% CI 2.90-3.40) more than threefold.6,7 Randomized clinical trials (RCTs) and retrospective observational studies reported that sodium-glucose cotransporter-2 inhibitors (SGLT2) inhib…”
BackgroundResultInfluentialSantos, G. L., dos Santos, C. F., Rocha, G. R., Calmon, M. S., Lemos, F. F. B., Silva, L. G., Luz, M. S., Pinheiro, S. L. R., Botelho, A. C., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104706 · Cited by 11
“…use - very similar from what is observed in RAS inhibitors - the filtration rate remained stable and discontinuation of the drug led to a recovery in the initially lost eGFR, while the placebo group exhibited a continuous decline in eGFR values over time, leading to faster CKD progression[68,69].”
Hadjadj, S., Cooper, M. E., Steubl, D., Petrini, M., Hantel, S., Mattheus, M., Wanner, C., & Thomas, M. C. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100783 · Cited by 10
“42-44 Indeed, SGLT2 inhibition is associated with an initial decrease in eGFR of 3-5 mL/min/1.73 m 2 shortly after treatment initiation, 6,16,45,46 which may lead to an un-derestimation of the true effect of SGLT2 inhibition to stabilize kidney function over a longer period of time.”
BackgroundMethodInfluentialSelf-citationSingh, K. K., Kondal, D., Jagannathan, R., Ali, M. K., Prabhakaran, D., Narayan, K. M. V., Anand, S., & Tandon, N. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004218 · Cited by 10
Blood pressure targets in chronic kidney disease: an update on the evidence
Guerrot, D., & Humalda, J. K. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000601 · Cited by 10
Overhydration: A cause or an effect of kidney damage and how to treat it
Szymczak, A., Kusztal, M. A., & Krajewska, M. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/132035 · Cited by 9
Wu, T., Wong, C. K. H., Tang, E. H. M., Man, K. K. C., Wong, S. K., Au, I. C. H., Tse, E. T. Y., Chan, E. W., Grieve, E., Wu, O., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.02.008 · Cited by 9
Kanaoka, T., Wakui, H., Yano, Y., Nagasu, H., Kanegae, H., Nangaku, M., Hirakawa, Y., Nakagawa, N., Wada, J., Tsuruya, K., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15611 · Cited by 9
“8,9 In our previous study of the J-CKD-DB, we also observed that patients treated with an SGLT2 inhibitor exhibited the phenomenon of this initial drop.”
Kaku, K., Yamamoto, K., Fukushima, Y., Mizuno, S., & Nitta, D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2062322 · Cited by 9
Iida, T., Hosojima, M., Kabasawa, H., Yamamoto-Kabasawa, K., Goto, S., Tanaka, T., Kitamura, N., Nakada, M., Itoh, S., Ogasawara, S., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108312 · Cited by 9
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction
Rastogi, T., & Girerd, N. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.006 · Cited by 9
Hirai, T., Kitada, M., Monno, I., Oda, E., Hayashi, Y., Shimada, K., Takagaki, Y., Ogura, Y., Fujii, M., Konishi, K., et al. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13502 · Cited by 9
Kwan, A. Y. M., Gerstein, H. C., Basile, J., Xavier, D., Maldonado, J. M., Raha, S., & Кониг, М. (2022) · Diabetes Care · doi:10.2337/dc21-1160 · Cited by 9
Ercis, M., Tarikogullari, I., Pazdernik, V. K., Suarez, M. L. G., Baweja, R., Miola, A., Abulseoud, O. A., Leung, J. G., McElroy, S. L., Barboza, A. B. C., et al. (2026) · Bipolar Disorders · doi:10.1111/bdi.70094 · Cited by 8
“Although this rate is higher than those reported in clinical trials [21, 23, 38], it is comparable to the real-world at least one discontinuation rates (ranging from 37.7% to 56”
InfluentialRenal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease
Zhou, T., Yao, K., Xie, Y., Lin, Y., Wang, J., & Chen, X. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230804103643 · Cited by 8
An, H.-J., Jang, J. H., Lee, S., Kim, S. G., Song, H. J., Noh, H., & Kim, J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111796 · Cited by 8
Sugiyama, S., Yoshida, A., Hieshima, K., Kurinami, N., Jinnouchi, K., Tanaka, M., Suzuki, T., MIYAMOTO, F., Kajiwara, K., Jinnouchi, T., et al. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4351 · Cited by 7
“Although SGLT2i therapy produces IAD-eGFR, it is thought that the subsequent rate of eGFR decrease (slope) becomes slower and exerts renoprotective effects in the long term [11].”
BackgroundLiang, B., Li, R., Zhang, P., & Gu, N. (2022) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-022-10302-4 · Cited by 6
“73 m2)) [45], and the reduction in intraglomerular pressure of empagliflozin may contribute to the long-term preservation of kidney function [100].”
BackgroundWeingold, R., Zinman, B., Mattheus, M., Ofstad, A. P., Steubl, D., Wanner, C., & Inzucchi, S. E. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108628 · Cited by 6
Self-citationShakour, N., Hoseinpoor, S., Sepehri, S., Iranshahi, M., Badpeyma, M., & Hadizadeh, F. (2024) · Journal of Computational Science · doi:10.1016/j.jocs.2024.102497 · Cited by 6
Spanopoulos, D., Okhai, H., Zaccardi, F., Tebboth, A., Barrett, B. J., Busse, M., Webb, J., & Khunti, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13734 · Cited by 6
Kardiovaskuläre Pharmakotherapie und koronare Revaskularisation bei terminaler Niereninsuffizienz
Lauder, L., Ewen, S., Emrich, I. E., Böhm, M., & Mahfoud, F. (2019) · Herz · doi:10.1007/s00059-019-04846-6 · Cited by 6
Are All SGLT2 Inhibitors Created Equal?
Gregg, L. P., & Navaneethan, S. D. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09720721 · Cited by 6
Treatment of acromegaly-induced diabetes: an updated proposal
Biagetti, B., Castro, M. A., Marazuela, M., & Puig‐Domingo, M. (2024) · Pituitary · doi:10.1007/s11102-024-01477-x · Cited by 5
“…neurocognitive dysfunction and GLP-1RAs have shown neuroprotective 1 3 mortality in T2DM patients by 35% in just the first year of treatment [ 80, 81] and have thus been currently included in also the treatment of cardiac failure of non-T2DM patients and in chronic kidney disease; thereby,…”
Song, Y., Zhou, H., Ye, L., Liu, Y., Guo, F., & Qin, G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70463 · Cited by 5
Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease
Hu, S., Lee, K., He, C., & Fan, Y. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001053 · Cited by 5
Efficacy and safety of Sodium-Glucose-Transporter-2 inhibitors in kidney transplant patients
Jenssen, T. G. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000749 · Cited by 5
“This is what is believed to be primary mechanism both in patients with [16,23] and without [15 & ,18 & ] diabetes.”
BackgroundMiyamoto, S., Heerspink, H. J. L., de Zeeuw, D., Toyoda, M., Suzuki, D., Hatanaka, T., Nakamura, T., Kamei, S., Murao, S., Hida, K., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14731 · Cited by 5
Self-citationAl‐Sodany, E., Chesnaye, N. C., Heimbürger, O., Jager, K. J., Barany, P. F., & Evans, M. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003168 · Cited by 5
Lundqvist, M., Patsoukaki, V., Jansson, S. P. O., Norman, H. L., Granstam, E., Svensson, M. K. E., Sundström, J., Eliasson, B., & Eriksson, J. W. (2023) · Diabetes and Vascular Disease Research · doi:10.1177/14791641231179878 · Cited by 5
“The rationale behind the 12-month limit is the welldescribed temporary drop in eGFR that occurs immediately after treatment initiation with SGLT2-inhibitors and remains up to 12 months compared with placebo.(8,18,19) Development or progression of albuminuria, foot complications and retinopathy were defined as the prog…”
Weinrauch, L. A., Liu, J., Segal, A. R., Woodward, J., & D’Elia, J. A. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107761 · Cited by 5
Role of metabolic conditions in cardiorenal diseases: initiating pathways and therapeutic targeting
Wu, Y., Xu, H., Tu, X., & Gao, Z. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1701084 · Cited by 4
Elyan, B. M. P., Sullivan, M. K., Hedley, J., Mata, N. L. D. L., Webster, A. C., Venugopal, B., Jones, R. J., Lang, N. N., Mark, P. B., & Lees, J. S. (2024) · BJC Reports · doi:10.1038/s44276-024-00081-7 · Cited by 4
“…important marker of kidney function decline and a surrogate marker for future kidney failure [23 – 25]. eGFR slope over 2 – 3 years is now routinely used as a critical outcome to delineate differences in the rate of kidney function decline for on-and off-treatment effects in clinical trials [26].”
BackgroundEriksen, B. O., Fasiolo, M., Mathisen, U. D., Jenssen, T. G., Norvik, J. V., Schei, J., Stefansson, V. T. N., & Melsom, T. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf079 · Cited by 4
Hamaguchi, M., Hashimoto, Y., Tanaka, T., Hasegawa, G., Ishii, M., Okada, H., Mitsuhashi, K., Kitagawa, N., Ushigome, E., Yamazaki, M., et al. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211040539 · Cited by 4
Kaku, K., Nakayama, Y., Yabuuchi, J., Naito, Y., & Kanasaki, K. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2213477 · Cited by 4
“decline relative to placebo over the long term [46].”
Murofushi, T., Yagi, T., Tsuji, D., Furushima, D., Fujikura, T., Itoh, K., & Kawakami, J. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02890-y · Cited by 4
“Studies using the eGFR slope have been conducted, such as with respect to the progression of renal-related diseases (Inker et al. 2021; Troost et al. 2021) and the renoprotective effects of sodium-glucose cotransporter-2 inhibitors (Yokouchi et al. 2022; Wanner et al. 2018).”
Evaluation and Management of Obesity in Chronic Kidney Disease
Friedman, A. N. (2025) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2025.07.004 · Cited by 4
Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220831151645 · Cited by 4
van der Hoek, S., Koomen, J. V., van Bommel, E. J. M., Mosterd, C. M., Scholtes, R. A., Hesp, A. C., Stevens, J., van Raalte, D. H., & Heerspink, H. J. L. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050747 · Cited by 4
“This reduction in glomerular hyperfiltration is clinically manifested by an acute reduction in estimated glomerular filtration rate (eGFR) and is associated with a slower eGFR decline during prolonged treatment compared to placebo, indicating kidney preservation [12].”
BackgroundSelf-citationCherney, D. Z. I., Cosentino, F., McGuire, D. K., Kolkailah, A. A., Dagogo-Jack, S. E., Pratley, R. E., Frederich, R. C., Maldonado, M., Liu, C., & Cannon, C. P. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.01.011 · Cited by 4
Small, A. M., & Wiviott, S. D. (2024) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06600-6 · Cited by 3
Rizk, M. A., El-Haggar, S. M., Ibrahim, O. M., & Ghazi, H. A. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109175 · Cited by 3
杨, 小. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.144980 · Cited by 3
Acute Renal Failure With Cocaine and SGLT-2 Inhibitor
Shrivastava, S., Srivastava, N., & Alfonso-Jaume, M. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000929 · Cited by 3
Martínez, J. J. G., Brito-Sanfiel, M. Á., Antón-Bravo, T., Sanz-Pastor, A. G., WONG-CRUZ, J. E. M., & Fernández, M. A. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195622 · Cited by 3
“In several clinical trials, the absolute effect of SGLT-2is on eGFR slope was greater in people with severely increased albuminuria and this was due to the much more rapid decline in kidney function in these patients [16,17].”
BackgroundHirai, A., Sakai, T., & Umezu, J. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.937 · Cited by 3
Hamaguchi, M., Yoshimura, Y., Nakajima, H., Tanaka, T., Hasegawa, G., Ishii, M., Okada, H., Mitsuhashi, K., Kitagawa, N., Okamura, T., et al. (2022) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.22-7 · Cited by 3
“(10,14) However, SGLT2 inhibitors are associated with a greater number of adverse events, including hypoglycemia and ketoacidosis.”
Effects of Diabetes and Insulin Resistance on Endothelial Functions
Fu, J., Yu, M. G., Li, Q., Park, K., & King, G. L. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_3 · Cited by 2
Korbut, A. I., Ananishnikova, E. A., Орлов, Н. Б., Bgatova, N. P., Muraleva, N. A., Zavyalov, E. L., Konenkov, V. I., & Klimontov, V. V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146483 · Cited by 2
“Beneficial cardiac and renal effects were significant for 12 months after the discontinuation of empagliflozin treatment [24,26].”
Evidencias de los iSGLT2 en el tratamiento de la enfermedad renal crónica
Montero, A. C. (2023) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2023.102019 · Cited by 2
Sano, Y., Jin, R., Yoshioka, H., Nakazato, Y., Sato, H., & Hisaka, A. (2025) · Clinical and Translational Science · doi:10.1111/cts.70351 · Cited by 2
“…− 1.49 mL/min/1.73 m 2 over a long disease period of 30 years, which is consistent with the EMPA-REG OUTCOME trial in patients with type 2 diabetes; the decline rate was − 1.46 mL/min/1.73 m 2 (95% confidence interval, − 1.74 to − 1.17) over a 3.1-year observation period in the placebo group [26].”
InfluentialMetabolic effects of empagliflozine
Кедик, А. В., & Kutsin, O. O. (2022) · Diabetes Obesity Metabolic Syndrome · doi:10.57105/2415-7252-2022-5-04 · Cited by 3
Abat, S., Abd Rahman, R., Cader, R. A., Abdul Hafidz, M., Abdul Wahab, M., Abdullah, N., Abdulsamad, T., Abe, M., Abraham, N., Acheampong, S., et al. (2023) · UCL Discovery (University College London) · Cited by 2
Crabtree, T. S. J., Bickerton, A. S. T., Elliott, D., Raghavan, R., Barnes, D., Sivappriyan, S., Phillips, S. M., Evans, A. J., SENNIK, D. K., Rohilla, A., et al. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.288 · Cited by 2
Метаболічні ефекти інгібіторів натрійзалежного котранспортера глюкози 2 типу
Кедик, А. В., & Kutsin, O. O. (2022) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2022-4-42 · Cited by 2
Kimmel, A. S., Magargal, L. E., & Goldberg, R. E. (1989) · PubMed · Cited by 2
Bhandari, S., Mehta, S. P., Khwaja, A., Cleland, J. G. F., Ives, N. J., Brettell, E. A., Chadburn, M., Cockwell, P., & for the STOP-ACEi Trial Investigators (2024) · Efficacy and Mechanism Evaluation · doi:10.3310/ttmc6210 · Cited by 1
Gîrdan, L., Gavris, C. M., & Nedelcu, L. D. (2024) · Jurnal Medical Brasovean · doi:10.31926/jmb.2023.1.4 · Cited by 1
The synergistic treatment of heart and kidney disease
Mahfoud, F., Götzinger, F., Kramann, R., Marx, N., & Schwenger, V. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0131 · Cited by 1
Khan, Z., Altaf, A., Jahanzaib, S., Ijaz, M. U., Fazal, N., & Ikhlaq, A. (2025) · Life and Science · doi:10.37185/lns.1.1.870 · Cited by 1
Aktuelles zur evidenzbasierten medikamentösen Herzinsuffizienztherapie
Emrich, I. E., Wintrich, J., Kindermann, I., & Böhm, M. (2019) · Herz · doi:10.1007/s00059-019-4827-2 · Cited by 1
Fong, M.-C., Feng, A., Yin, W., Tsao, T., & Chang, H. (2021) · HeartRhythm Case Reports · doi:10.1016/j.hrcr.2021.02.009 · Cited by 1
Rossing, P. R., & Persson, F. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.002 · Cited by 1
Putting it All Together: Practical Approach to the Patient with Diabetic Kidney Disease
Eng, E., & Quaggin, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_29 · Cited by 1
Precision medicine in type 2 diabetes
Dennis, J. (2019) · Figshare · Cited by 1
SGLT2 Inhibitors across the Spectrum of Severity of CKD
Ziaolhagh, A., & Argyropoulos, C. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.13430820 · Cited by 1
Renal transplant outcomes and diabetes
Weinrauch, L. A., & D’Elia, J. A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002294 · Cited by 1
Lam, S. H. M., Alam, U., & Lip, G. Y. H. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.05.001 · Cited by 1
Quintanilla Lora, M. J. A., & Quintanilla Lora, M. J. A. (2021) · ALICIA National Digital Repository (Antenor Orrego Private University) · Cited by 1
Emrich, I. E., Böhm, M., & Mahfoud, F. (2019) · Aktuelle Kardiologie · doi:10.1055/a-1029-8295
“Eine im letzten Jahr veröffentlichte Sekundäranalyse der EMPA‐REG Outcome-Studie konnte weiterhin zeigen, dass es im Behandlungsarm zu einer Verlangsamung der renalen Funktionsverschlechterung kommt [33].”
BackgroundVII. Efforts for Prevention of Severe Diabetic Kidney Disease (DKD) in Community Medicine
Kondo, S., Masutomo, K., & Fujino, T. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.944
Renovaskuläre Effekte von SGLT-2-Inhibitoren
Hohenstein, B., & Hugo, C. (2020) · Diabetes aktuell · doi:10.1055/a-1152-2146
“LEADER Trial [7]), als auch unter Einsatz der SGLT2-Inhibitoren [8, 9] unterstützen diese Sichtweise.”
BackgroundExtending the use of SGLT2 inhibitors from diabetic to non-diabetic kidney disease
Dekkers, C. C. J. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.136049658
Mikhai, N. (2021) · International Journal of Diabetology & Vascular Disease Research · doi:10.19070/2328-353x-2100050
Electrolyte disturbances in heart failure: focus on sodium and potassium
Beusekamp, J. C. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.196047233
Williams, M. E., & Stanton, R. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818540-7.00006-9
Hamaguchi, M., Hashimoto, Y., Tanaka, T., Hasegawa, G., Ishii, M., Okada, H., Mitsuhashi, K., Kitagawa, N., Ushigome, E., Yamazaki, M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-52292/v3
“Thus, SGLT2 inhibitors prevent cardiovascular complications in patients with type 1 diabetes mellitus, as reported in patients with type 2 diabetes mellitus [14, 24].”
BackgroundHamaguchi, M., Hashimoto, Y., Tanaka, T., Hasegawa, G., Ishii, M., Okada, H., Mitsuhashi, K., Kitagawa, N., Ushigome, E., Yamazaki, M., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-52292/v2
International Journal of Diabetology & Vascular Disease Research
Bellotti, F., Kapralos, B., Lee, K., & Moreno-Ger, P. (2022) · International Journal of Diabetology & Vascular Disease Research · doi:10.19070/2328-353x
Kramer, H., & Navaneethan, S. D. (2019) · Nephrology Self-Assessment Program · doi:10.1681/nsap.2019.18.4.6
Hamaguchi, M., Hashimoto, Y., Tanaka, T., Hasegawa, G., Ishii, M., Okada, H., Mitsuhashi, K., Kitagawa, N., Ushigome, E., Yamazaki, M., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-52292/v1
“In addition, since SGLT2 inhibitors prevents cardiovascular complications in patients with type 2 diabetes mellitus [6], the bene cial effects of the SGLT2 inhibitors are also expected in patients with T1DM [7].”
BackgroundWhat Is the Best Medicine for Chronic Kidney Disease in Diabetes?
Giaccari, A. (2022) · Diabetes Care · doi:10.2337/dci22-0029
Berthelot, E. (2022) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2022.11.010
Cardiorenal Syndrome 1: What’s in a Name?
Schaubroeck, H., Vandenberghe, W., & Hoste, E. A. J. (2023) · Annual update in intensive care and emergency medicine · doi:10.1007/978-3-031-23005-9_27
der Beek, A. B. V. D. A. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.637600695
Mechanisms of SGLT2 inhibition in the kidney: from mechanism towards biomarker guided therapy
Sen, T. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.659987622
Using PET imaging as tool to unravel drug response variability in type 2 diabetes
van der Hoek, S. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.845383131
Kardiológiai újdonságok és szakmai irányelvek, amelyek a krónikus vesebetegeket is érinthetik
Schneider, K. (2024) · Hypertonia és Nephrologia · doi:10.33668/hn.28.003
Metadata
- Authors
- Wanner, C., Heerspink, H. J. L., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U. C., von Eynatten, M., Groop, P.-H., & on behalf of the EMPA-REG OUTCOME Investigators
- Affiliations
- Universitätsklinikum Würzburg (DE)
- University Medical Center Groningen (NL)
- Mount Sinai Hospital (CA)
- Yale University (US)
- Division of Nephrology, Department of Medicine, Würzburg University Clinic, Würzburg, Germany;
- Boehringer Ingelheim (Germany) (DE)
- Universität Ulm (DE)
- Boehringer Ingelheim International GmbH, Ingelheim, Germany;
- University of Helsinki (FI)
- Corresponding author
- Wanner, Christoph
- ORCID
- Venue
- Journal of the American Society of Nephrology
- Published
- 2018-10-12
- Volume
- 29
- Issue
- 11
- Pages
- 2755-2769
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- PMC
- PMC6218863
- OpenAlex
- W2897993744
- Cited by
- 209
- References
- 27
- Citations by year
- 2026: 15 · 2025: 12 · 2024: 22 · 2023: 35 · 2022: 38 · 2021: 31 · 2020: 29 · 2019: 25 · 2018: 1
- FWCI
- 17.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Lirias (KU Leuven) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- American Society of Nephrology
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- empagliflozin, renal function decline, type 2 diabetes, estimated glomerular filtration rate, eGFR slope, chronic kidney disease, EMPA-REG OUTCOME trial, SGLT2 inhibitors, drug discontinuation, renal function recovery, hemodynamic effects, cardiovascular risk reduction
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glomerular Filtration Rate, Glucosides, Humans, Male, Middle Aged, Models, Statistical, Cohort Studies, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.